Just a couple of weeks after securing U.S. Food and Drug Administration approval for its implant to treat obstructive sleep apnea, Inspire Medical Systems added three new investors in a Series E round raising $40 million. OrbiMed led the financing round and its private equity partner, Chau Q. Khuong, will sit on the board. Johnson […]
Sleep is like sex. Everybody wants it and nobody is getting enough. That’s what Lars Knutsen of Requis Pharmaceuticals said the other day as part of a presentation for a snoring and sleeplessness treatment. But it’s just as relevant for the 18 million people who deal with obstructive sleep apnea. Although continuous positive airway pressure […]
Inspire Medical Systems, which has developed an implantable neurostimulation device to treat sleep apnea, announced Friday that it has raised $14.5 million in a series C round. New investors include Medtronic, which licensed the technology to Inspire back in 2007, and TGap Venture, while existing investors, Kleiner Perkins Caufield & Byers, US Venture Partners, Synergy […]
Medtronic Inc. spinout Inspire Medical Systems Inc. has received the go-ahead from regulators to sell its obstructive sleep apnea device in Europe and test it for the U.S. market.
Apnex Medical Inc., a St. Paul-based startup developing technology to treat obstructive sleep apnea (OSA), has named Charles McKhann as its new CEO. McKhann, who previously served as a global vice president of marketing for Boston Scientific Corp.’s (NYSE: BSX) cardiac rhythm management division, replaces founder and executive director Robert Atkinson. While at Johnson & […]
A couple of Midwest biomedical companies announced new venture financing this week. Could the deep freeze for early-stage investments be thawing?
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Inspire Medical Systems Inc. in Minneapolis has raised $17 million in a second round of venture capital to pay for ongoing clinical trials of its device to treat one type of sleep apnea.
